The Know AML website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and Know AML cannot guarantee the accuracy of translated content. Know AML and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

About Us

What were the key takeaways on trials from ASH 2019?

Agnieszka Wierzbowska

December 12, 2019

During the 61st American Society of Hematology (ASH) meeting in Orlando, US, Know AML were pleased to speak to Agnieszka Wierzbowska, Copernicus Memorial Hospital, Lodz, PL. We asked Agnieszka Wierzbowska: What were the key messages from the most promising trials presented at ASH? Agnieszka Wierzbowska discusses the anticipated results from the QUAZAR AML-001 study, that was dedicated to examining the role of maintenance chemotherapy in treating elderly patients with acute myeloid leukemia. She also talks about the importance of cytogenetic stratification to guide patient treatment, so that patients can receive targeted therapy. She explains that this approach has benefited patients overall survival.